Physician profile
Benjamin D Schmidt
NPI 1710418819
$52,202.24
in general payments reported to CMS, 2019-2025
24 companies · $29K in 2025
The $29K reported for 2025 was more than what 96% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $8,421 · 2023: $13K · 2024: $2,123 · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $27K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,000 · Food and Beverage: $4,736 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $4,200 · Education: $45.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $26,800.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,000.00 |
| Food and Beverage | $4,735.71 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $4,200.00 |
| Education | $45.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $18,426.26 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12,914.22 | 2022-2025 | Plenvu, Xifaxan |
| Abbvie INC. | $8,950.25 | 2023-2025 | Rinvoq, Skyrizi, Humira |
| Kci USA, INC. | $8,000.00 | 2023 | Littmann Telesteth |
| Genzyme Corporation | $1,678.89 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $306.10 | 2023-2025 | Entyvio, Eohilia |
| Intercept Pharmaceuticals, INC. | $271.00 | 2023-2025 | Ocaliva |
| Janssen Biotech, INC. | $194.11 | 2023-2025 | Stelara, Tremfya, Simponi Aria |
| Gilead Sciences, INC. | $186.91 | 2023-2025 | Livdelzi |
| Lilly USA, LLC | $186.31 | 2024-2025 | Omvoh |
| Celgene Corporation | $177.36 | 2023-2024 | Zeposia |
| Ardelyx, INC. | $145.36 | 2023-2024 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $113.23 | 2024-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $108.99 | 2023-2024 | Dificid, Zinplava |
| Aimmune Therapeutics, INC. | $101.46 | 2024-2025 | Zenpep, Vowst |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $96.91 | 2024-2025 | Zymfentra, Vegzelma |
| Cook Medical LLC | $79.20 | 2025 | Zilver Ptx |
| Ironwood Pharmaceuticals, INC | $70.21 | 2023-2025 | Linzess |
| Organon LLC | $45.51 | 2025 | Hadlima |
| Boston Scientific Corporation | $42.28 | 2022-2025 | General - Gi Dilatation |
| Madrigal Pharmaceuticals | $36.27 | 2024-2025 | Resmetirom, Rezdiffra |
| Phathom Pharmaceuticals, INC. | $35.76 | 2025 | Voquezna |
| Pharmacosmos Therapeutics INC. | $20.54 | 2023 | Monoferric |
| Nestle Healthcare Nutrition INC. | $15.11 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Schmidt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.